‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*
Tóm tắt
Từ khóa
Tài liệu tham khảo
Khoury MJ. Human Genome Epidemiology (HuGE): translating advances in human genetics into population-based data for medicine and public health. Genet Med1999;1:71–73.
Khoury MJ, Burke W, Thomson EJ (eds). Genetics and Public Health in the 21st Century. Oxford: Oxford University Press, 2000, pp. 10–11.
Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet;357:709–12.
Ames BN. Cancer prevention and diet: Help from single nucleotide polymorphisms. PNAS1999;96:12216–18.
Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochimica Biophysica Acta2001;1471:C1–C10.
Brennan P. Gene environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis2002; 23:381–87.
Youngman LD, Keavney BD, Palmer A et al. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by ‘Mendelian randomization’. Circulation2000;102(Suppl.II):31–32.
Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet2001; 358:1356–60.
Fallon UB, Ben-Shlomo Y, Davey Smith G. Homocysteine and coronary heart disease. Heart Online 14 March 2001 (http://heart.bmjjournals.com/cgi/eletters/85/2/153)
Keavney B. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol2002;31:730–36.
Feinstein AR. Scientific standards in epidemiologic studies of the menace of daily life. Science1988;242:1257–63.
Skrabanek P. False Premises, False Promises. Whithorn: Tarragon Press, 2000.
Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature1981;290:201–08.
Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med1994;330: 1029–35.
Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med1996;334:1150–55.
Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med1996;334:1145–49.
Hooper L, Ness AR, Davey Smith G. Antioxidant strategy for cardiovascular diseases. Lancet2001;357:1705–06.
Khaw K-T, Bingham S, Welch A et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet2001; 357:657–63.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:23–33.
Davey Smith G, Phillips AN. Confounding in epidemiological studies: why ‘independent’ effects may not be all they seem. BMJ1992;305: 757–59.
Phillips A, Davey Smith G. How independent are ‘independent’ effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol1991;44:1223–31.
Phillips AN, Davey Smith G. The design of prospective epidemiological studies: more subjects or better measurements? J Clin Epidemiol1993; 46:1203–11.
Weiss NS. Can the ‘specificity’ of an association be rehabilitated as a basis for supporting a causal hypothesis? Epidemiology2002;13:6–8.
Petitti DB, Perlman JA, Sidney S. Postmenopausal estrogen use and heart disease. N Engl J Med1986;315:131–32.
Phillips A. Balancing quantity and quality when designing epidemiological studies. Int J Epidemiol2003;32:58–59.
Phillips AN, Davey Smith G. Cigarette smoking as a potential cause of cervical cancer: has confounding been controlled? Int J Epidemiol1994;23:42–49.
Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant1991;7(Suppl.3):9–12.
Ljungman P, De Witte T, Verdonck L et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. Br J Haematol1993;84:61–66.
Keating S, de Witte T, Suciu S et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMENA. Br J Haematol1998;102:1344–53.
Burnett AK, Wheatley K, Goldstone AH et al. The value of allogenic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol2002;118:385–400.
Bleakley M, Shaw PJ, Nielsen JM. Allogenic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor. Bone Marrow Transplant2002;31:1–7.
Harrison G, Richards S, Lawson S et al. on behalf of the MRC Childhood Leukaemia Working Party. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. Ann Oncol2000;11: 999–1006.
Mendel G. Experiments in Plant Hybridization (1865). http://www.mendelweb.org/archive/Mendel.Experiments.txt (accessed 12 Dec 2002).
Elston R, Olson J, Palmer L (eds). Biostatistical Genetics and Genetic Epidemiology. Chichester: John Wiley & Sons, 2002, p. 285.
Terwilliger JD, Goring HHH. Gene mapping in the 20th and 21st centuries: statistical methods, data analysis and experimental design. Hum Biol2000;72:63–132.
Talking Glossary: National Human Genome Research Institute. www.genome.gov/glossary.cfm (accessed 12 Dec 2002).
Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet1993;52:506–16.
Ahsan H, Hodge SE, Heiman GA, Begg MD, Susser ES. Relative risk for genetic associations: the case-parent triad as a variant of case-cohort design. Int J Epidemiol2002;31:669–78.
Garcia-Palmiere MR, Sorlie PD, Costas R, Havlik RJ. An apparent inverse relationship between serum cholesterol and cancer mortality in Puerto Rico. Am J Epidemiol1981;114:29–40.
McMichael AJ, Jensen OM, Parkin DM, Zaridze DG. Dietary and endogenous cholesterol and human cancer. Epidemiol Rev1984;6:192–216.
Wessel N, Liestol K, Maehlen J, Brorson SH. The apolipoprotein E epsilon4 allele is no risk factor for prostate cancer in the Norwegian population. Br J Cancer2001;85:1418.
Niemi M, Kervinen K, Kiviniemi H et al. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health2000;54:938–39.
Moysich KB, Freudenheim JL, Baker JA et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog2000;27:2–9.
Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol2002;31:59–70.
Homocysteine Lowering Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized controlled trials. BMJ1998;316:894–98.
Brattstro″m L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr2000;72:315–23.
Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr2000;72:324–32.
Clarke R. An updated review of the published studies of homocysteine and cardiovascular disease. Int J Epidemiol2002;31:70–71.
Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12 and vitamin B6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. JAMA2002;288:973–79.
Schnyder G, Roffi M, Flammer Y et al. Decreased rate of coronary restenosis with lowering of plasma homocysteine levels. N Engl J Med2001;345:1593–600.
Vermeulen E. Stehouwer C, Twisk J et al. Effect of homocysteine lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomized placebo controlled trial. Lancet2000;355:517–22.
Brattström L, Wilcken D, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation1998;98:2520–26.
The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA2002;288: 2015–22.
Klerk M, Verhoef P, Clarke R et al. MTHFR 677C→T polymorphism and risk of coronary heart disease. A meta-analysis. JAMA2002;288: 2023–31.
Clarke R, Lewington S, Donald A et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk2001;8:363–69.
Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr2000;71(Suppl.):1295S–303S.
MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the Medical Research Council vitamin study. Lancet1991;338:131–37.
Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. New Engl J Med1992;327:1832–35.
Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE Review. Am J Epidemiol2000;151:862–77.
Steegers-Theunissen RPM, Boers GHJ, Trijbels FJM et al. Maternal hyperhomocysteinemia: a risk factor for neural tube defects? Metabolism1994;43:1475–80.
Rosenquist TH, Finnell RH. Genes, folate and homocysteine in embryonic development. Proc Nutr Soc2001;60:53–61.
Mills JL, McPartlin MJ, Kirke PN et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet1995;345: 149–51.
Andersson A, Hultberg B, Brattstrom L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem1992;30: 377–79.
Anonymous. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet1991;338:131–37.
Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study. Am J Clin Nutr2000;71:962–68.
Marugame T, Tsuji E, Kiyohara C et al. Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal cancer. Int J Epidemiol2003;32:64–66.
Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res2001;475:57–67.
Houlston RS, Tomlinson IPM. Polymorphisms and colorectal tumor risk. Gastroenterology2001;121:282–301.
Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control2002;13:239–48.
Franco RF, Simões BP, Tone LG, Gabellini SM, Zago MA, Falcão. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol2001;115:616–18.
Skibola CF, Smith MT, Kane E et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibil-ity to acute leukemia in adults. Proc Natl Acad Sci USA1999; 96:12810–15.
Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis1997;18:869–82.
Marmot M. Commentary: Reflections on alcohol and coronary heart disease. Int J Epidemiol2001;30:729–34.
Bovet P, Paccaud F. Commentary: Alcohol, coronary heart disease and public health: which evidence-based policy? Int J Epidemiol2001;30:734–37.
Klatsky AL. Commentary: Could abstinence from alcohol be hazardous to your health? Int J Epidemiol2001;30:739–42.
Hart CL, Davey Smith G, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of Scottish men with 21 years of follow up. BMJ1999;318:1725–29.
Rimm E. Commentary: Alcohol and coronary heart disease—laying the foundation for future work. Int J Epidemiol2001;30:738–39.
Eriksson CJP, Fukunaga T, Sarkola T et al. Functional relevance of human ADH polymorphism. Alcohol Clin Exp Res2001;25:157S–63S.
Whitfield JB, Nightingale BN, Bucholz KK, Madden PAF, Heath AC, Martin NG. ADH Genotypes and alcohol use and dependence in Europeans. Alcohol Clin Exp Res1998;22:1463–69.
Hines LM, Stampfer MJ, Ma J et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med2001;344: 549–55.
Tadel M, Goldman D. Pharmacogenetics of alcohol response and alcoholism: the interplay of genes and environmental factors in thresholds for alcoholism. Drug Metabolism and Disposition2001;29: 489–94.
Sun F, Tsuritani I, Yamada Y. Contribution of genetic polymorphisms in ethanol-metabolizing enzymes to problem drinking behavior in middle-aged Japanese men. Behav Genet2002;32:229–36.
Nakamura Y, Amamoto K, Tamaki S et al. Genetic variation in aldehyde dehydrogenase 2 and the effect of alcohol consumption on cholesterol levels. Atherosclerosis2002;164:171–77.
Haskell WL, Camargo C, Williams PT et al. The effect of cessation and resumption of moderate alcohol intake on serum high-density-lipoprotein subfractions. N Engl J Med1984;310:805–10.
Burr ML, Fehily AM, Butland BK et al. Alcohol and high-density-lipoprotein cholesterol: a randomized controlled trial. Br J Nutr1986;56:81–86.
Cherry N, Mackness M, Durrington P et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet2002;359:763–64.
D’Errico A, Taioli E, Chen X, Vineis P. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers1996;1:149–73.
Hein DW, Doll MA, Fretland AJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev2000;9:29–42.
Vineis P, McMichael AJ. Interplay between heterocyclic amines in cooked meat and metabolic phenotype in the aetiology of colon cancer. Cancer Causes Control1996;7:479–86.
Roberts-Thomson I, Ryan PR, Khoo K et al. Diet, acetylator phenotype and risk of colorectal neoplasia. Lancet1996;347: 1372–74.
Colhoun H, KcKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003, in press.
Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G_455→A) in the β-Fibrinogen promoter is an independent predictor of plama fibrinogen, but not of ischaemic heart disease. J Clin Invest1999:3034–39.
Van der Bom JG, De Maat MPM, Bots ML et al. Elevated plasma fibrinogen. Cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol1998;18:621–25.
Doggen CJM, Bertina RM, Manger Cats V, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol2000;110:935–38.
Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, c-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA1998;279:1477–82.
Brunner E, Davey Smith G, Marmot M, Canner R, Beksinska M, O’Brien J. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet1996;347:1008–13.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002; 324:71–86.
Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA1999;282:2058–67.
The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. The coronary drug project research group. JAMA1975;231:360–80.
Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ2002; 325:1139.
Ebrahim S, Davey Smith G, McCabe C et al. Cholesterol and coronary heart disease: screening and treatment. Qual Health Care1998;7:232–39.
Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ1991;303:893–96.
Hallman DM, Boerwinkle E, Saha N et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet1991;49:338–49.
Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res2000;41:1812–22.
Keavney BD, Youngman LD, Palmer A et al. Large-scale test of hypothesized associations between polymorphisms of lipid-related genes and myocardial infarction in about 5000 cases and 6000 controls. Circulation2000;102(Suppl.II):852.
Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis1988:8:1–21.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7–22.
Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE Review. Am J Epidemiol2002;155:487–95.
Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. Arterioscl Thromb Vasc Biol1996;16:1250–55.
http://www.ncbi.nlm.nih.gov/Omim (accessed 12 Dec 2002).
http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html (accessed 12 Dec 2002).
http://hgvbase.cgb.ki.se/about.htm (accessed 12 Dec 2002).
Langlois MR, Delanghe JR, De Buyzere ML, Bernard DR, Ouyang J. Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr1997;66:606–10.
Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis1999;145:287–92.
Delanghe J, Cambier B, Langlois M et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis1997;132:215–19.
De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H, Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis2001;157:161–66.
Cardon LR, Bell JI. Association study designs for complex diseases. Nature Rev: Genetics2001;2:91–99.
Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst2000;92:1151–58.
Wacholder S, Rothman N, Caporaso N. Counterpoint: Bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomark Prev2002;11:513–520.
Cardon LR, Palmer LJ. Wagging the dog? Population stratification and spurious allelic association. Lancet2003;361:598–604.
Sijbrands EJG, Westengorp RGJ, Defesche JC, De Meier PHEM, Smelt AHM, Kastelein JJP. Mortality over two centuries in large pedigrees with familial hypercholesterolaemia: family tree mortality study. BMJ2001;322:1019–23.
Pimstone SN, Sun X-M, Du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol1998;18:309–15.
Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genetics2002;3:391–97.
Stephens JC, Schneider JA, Tanguay DA et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science2001; 293:489–93.
Osier MV, Pakstis AJ, Soodyall H et al. A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity. Am J Hum Genet2002;71:84–99.
Waddington CH. Canalization of development and the inheritance of acquired characteristics. Nature1942;150:563–65.
Rutherford SL. From genotype to phenotype: buffering mechanisms and the storage of genetic information. BioEssays2000;22: 1095–105.
Gibson G, Wagner G. Canalization in evoluationary genetics: a stabilizing theory? BioEssays2000;22:372–80.
Hartman JL, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science2001;291:1001–04.
Debat V, David P. Mapping phenotypes: canalization, plasticity and developmental stability. Trends in Ecology and Evolution2001;16: 555–61.
Kitami T, Nadeau JH. Biochemical networking contributes more to genetic buffering in human and mouse metabolic pathways than does gene duplication. Nature Genet2002;32:191–94.
Gu Z, Steinmetz LM, Gu X, Scharfe C, Davis RW, Li W-H. Role of duplicate genes in genetic robustness against null mutations. Nature2003;421:63–66.
Morange M. The Misunderstood Gene. Cambridge: Harvard University Press, 2001.
Bolon B, Galbreath E. Use of genetically engineered mice in drug discovery and development: wielding Occam’s razor to prune the product portfolio. Int J Toxicol2002;21:55–64.
Gerlai R. Gene targeting: technical confounds and potential solutions in behavioural and brain research. Behavioural Brain Research2001;125:13–21.
Williams RS, Wagner PD. Transgenic animals in integrative biology: approaches and interpretations of outcome. J Appl Physiol2000; 88:1119–26.
Garry DJ, Ordway GA, Lorenz JN, Radford ER, Chin RW, Grange R et al. Mice without myoglobin. Nature1998;395:905–08.
Gabriel SE, Jaakimainen L, Bombardier C. Risk for serious gastro-intestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med1991;115: 787–96.
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci, USA 1999;96:7563–68.
Langenbach R, Morham SG, Tiano HF et al. Prostaglandin synthase gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell1995;83: 483–92.
Peskar BM. Role of cyclooxygenase isoforms in gastric mucosal defense. Journal of Physiology—Paris2001;95:3–9.
Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. British Journal of Pharmacology2001;132:1565–73.
Wright AF, Carothers AD, Campbell H. Gene-environment interactions—the BioBank UK study. Pharmacogenomics Journal2002;2:75–82.
Weiss K, Terwilliger J. How many diseases does it take to map a gene with SNPs? Nat Genet2000;26:151–57.
Erichsen HC, Eck P, Levine M, Chanock S. Characterization of the genomic structure of the human vitamin C transporter SVCT1 (SLC23A2). J Nutr2001;131:2623–27.
Mucci LA, Wedren S, Tamimi RM, Trichopoulos D, Adami HO. The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. Journal of Internal Medicine2001;249:477–93.
Chen J, Stampfer MJ, Hough HL et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res1998;58:3307–11.
Kampman E, Slattery ML, Bigler J et al. Meat consumption, genetic susceptibility, and colon cancer risk: a United States multi-center case-control study. Cancer Epidemiol Biomarkers Prev1999;8:15–24.
Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis1997;18:1351–54.
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastin survival Study (4S). Lancet1994;344:1383–89.
Heart Protection Study Collaborative Group. MRC/BHF heart protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals. Lancet2002;360:7–22.
Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995;333:1301–07.